GlassScriptPhysician profile
Karolina Poltorak
NPI 1629624564
$1,404.98
in general payments reported to CMS, 2019-2025
22 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $406 · 2022: $441 · 2023: $161 · 2024: $259 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $557 · Education: $0.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $557.12 |
| Education | $0.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $309.34 | 2021-2023 | |
| Ardelyx, INC. | $164.43 | 2024 | Xphozah 30 Mg, Ibsrela |
| Travere Therapeutics, INC. | $122.74 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $99.83 | 2021-2024 | Farxiga |
| Pfizer INC. | $90.43 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $80.98 | 2022-2025 | |
| Currax Pharmaceuticals LLC | $63.06 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $62.87 | 2025 | Voyxact, Jynarque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.30 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.49 | 2021-2022 | |
| Novo Nordisk INC | $47.27 | 2021-2022 | |
| Amarin Pharma, INC. | $42.32 | 2021-2022 | |
| Glaxosmithkline, LLC. | $28.18 | 2022 | |
| Arbor Pharmaceuticals, INC. | $25.47 | 2021 | |
| Endo Pharmaceuticals INC. | $24.90 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $24.05 | 2021 | |
| Optinose US, INC. | $22.54 | 2022 | |
| Akebia Therapeutics INC | $21.44 | 2022 | |
| Amneal Pharmaceuticals LLC | $19.85 | 2021 | |
| Eisai INC. | $18.72 | 2021 | |
| Ibsa Pharma INC. | $16.01 | 2022 | |
| Aurinia Pharma U.S., INC. | $15.76 | 2025 | Lupkynis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karolina Poltorak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.